Episode 3 - Managing novel DLBCL therapies in the community - what good looks like

Integrating novel therapies like bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs) into community oncology practices can be a complex process. On this episode of Bridges, Dr. Lunning and Dr. Graff speak with Dr. Iqra Choudary about how she integrated BsAbs and ADCs into her practice with a proactive multidisciplinary team, strong safety protocols, comprehensive staff training, and strategic hospital partnerships. Co-hosts: Dr. Matthew Lunning, MD, University of Nebraska Medical Center, and Dr. Tara Graff, MD, Mission Cancer & BloodGuest: Dr. Iqra Choudary, board certified in Internal Medicine, Hematology-Oncology Associates of Central New York